Endothelial dysfunction: The link between homocysteine and hydrogen sulfide

Current Medicinal Chemistry

Volumn 21, Issue 32, 2014, Pages 3662-3672

  Pushpakumar, Sathnur ^a   Kundu, Sourav ^a   Sen, Utpal ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Dysfunction; Endothelium; Homocysteine; Hydrogen sulfide

Indexed keywords

HOMOCYSTEINE; HYDROGEN SULFIDE;

AMINO ACID METABOLISM; ARTICLE; CELL INTERACTION; DNA METHYLATION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; INTRACELLULAR SIGNALING; LEUKOCYTE; NONHUMAN; OXIDATIVE STRESS; SYNTHESIS; THROMBOCYTE; BLOOD; METABOLISM; PHYSIOLOGY;

HOMOCYSTEINE; HUMANS; HYDROGEN SULFIDE; OXIDATIVE STRESS;

EID: 84918587720     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140706142335     Document Type: Article

References (142)

1. Furchgott, R. F.; Zawadzki, J. V., The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980, 288, (5789), 373-376.
2. Ignarro, L. J.; Buga, G. M.; Wood, K. S.; Byrns, R. E.; Chaudhuri, G., Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, (24), 9265-9269.
3. Chen, G.; Suzuki, H.; Weston, A. H., Acetylcholine releases endotheliumderived hyperpolarizing factor and EDRF from rat blood vessels. British journal of pharmacology, 1988, 95, (4), 1165-1174.
4. Dusting, G. J.; Moncada, S.; Mullane, K. M.; Vane, J. R., Implications of prostacyclin generation for modulation of vascular tone. Clinical science and molecular medicine. Supplement, 1978, 4, 195s-198s.
5. Moncada, S.; Higgs, E. A.; Vane, J. R., Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet, 1977, 1, (8001), 18-20.
6. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K.; Masaki, T., A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 1988, 332, (6163), 411-415.
7. Raz, A.; Minkes, M. S.; Needleman, P., Endoperoxides and thromboxanes. Structural determinants for platelet aggregation and vasoconstriction. Biochimica et biophysica acta, 1977, 488, (2), 305-311.
8. Tziros, C.; Freedman, J. E., The many antithrombotic actions of nitric oxide. Current drug targets, 2006, 7, (10), 1243-1251.
9. Momi, S.; Monopoli, A.; Alberti, P. F.; Falcinelli, E.; Corazzi, T.; Conti, V.; Miglietta, D.; Ongini, E.; Minuz, P.; Gresele, P., Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. Cardiovascular research, 2012, 94, (3), 428-438.
10. Tsihlis, N. D.; Oustwani, C. S.; Vavra, A. K.; Jiang, Q.; Keefer, L. K.; Kibbe, M. R., Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH10. Cell biochemistry and biophysics, 2011, 60, (1-2), 89-97.
11. Vallance, P.; Chan, N., Endothelial function and nitric oxide: clinical relevance. Heart, 2001, 85, (3), 342-350.
12. Hadi, H. A.; Suwaidi, J. A., Endothelial dysfunction in diabetes mellitus. Vascular health and risk management, 2007, 3, (6), 853-876.
13. Xu, J.; Zou, M. H., Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation, 2009, 120, (13), 1266-1286.
14. Yannoutsos, A.; Levy, B. I.; Safar, M. E.; Slama, G.; Blacher, J., Pathophysiology of hypertension: interactions between macro and microvascular alterations through endothelial dysfunction. Journal of hypertension, 2013.
15. Grammas, P.; Martinez, J.; Miller, B., Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert reviews in molecular medicine, 2011, 13, e19.
16. Hunt, B. J.; Jurd, K. M., Endothelial cell activation. A central pathophysiological process. Bmj, 1998, 316, (7141), 1328-1329.
17. Deanfield, J. E.; Halcox, J. P.; Rabelink, T. J., Endothelial function and dysfunction: testing and clinical relevance. Circulation, 2007, 115, (10), 1285-1295.
18. Boushey, C. J.; Beresford, S. A.; Omenn, G. S.; Motulsky, A. G., A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA: the journal of the American Medical Association, 1995, 274, (13), 1049-1057.
19. Homocysteine Studies, C., Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA: the journal of the American Medical Association, 2002, 288, (16), 2015-2022.
20. Nygard, O.; Nordrehaug, J. E.; Refsum, H.; Ueland, P. M.; Farstad, M.; Vollset, S. E., Plasma homocysteine levels and mortality in patients with coronary artery disease. The New England journal of medicine, 1997, 337, (4), 230-236.
21. Handy, D. E.; Zhang, Y.; Loscalzo, J., Homocysteine downregulates cellular glutathione peroxidase (GPx1) by decreasing translation. The Journal of biological chemistry, 2005, 280, (16), 15518-15525.
22. Zhou, J.; Werstuck, G. H.; Lhotak, S.; De Koning, A. B.; Sood, S. K.; Hossain, G. S.; Moller, J.; Ritskes-Hoitinga, M.; Falk, E.; Dayal, S.; Lentz, S. R.; Austin, R. C., Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice. Circulation, 2004, 110, (2), 207-213.
23. Jakubowski, H.; Zhang, L.; Bardeguez, A.; Aviv, A., Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circulation research, 2000, 87, (1), 45-51.
24. Li, L.; Rose, P.; Moore, P. K., Hydrogen sulfide and cell signaling. Annual review of pharmacology and toxicology, 2011, 51, 169-187.
25. Szabo, C., Roles of hydrogen sulfide in the pathogenesis of diabetes mellitus and its complications. Antioxidants & redox signaling, 2012, 17, (1), 68-80.
26. Kondo, K.; Bhushan, S.; King, A. L.; Prabhu, S. D.; Hamid, T.; Koenig, S.; Murohara, T.; Predmore, B. L.; Gojon, G., Sr.; Gojon, G., Jr.; Wang, R.; Karusula, N.; Nicholson, C. K.; Calvert, J. W.; Lefer, D. J., H (2) S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. Circulation, 2013, 127, (10), 1116-1127.
27. Mani, S.; Li, H.; Untereiner, A.; Wu, L.; Yang, G.; Austin, R. C.; Dickhout, J. G.; Lhotak, S.; Meng, Q. H.; Wang, R., Decreased endogenous production of hydrogen sulfide accelerates atherosclerosis. Circulation, 2013, 127, (25), 2523-2534.
28. Selhub, J., Homocysteine metabolism. Annual review of nutrition, 1999, 19, 217-246.
29. Ilhan, N.; Kucuksu, M.; Kaman, D.; Ilhan, N.; Ozbay, Y., The 677 C/T MTHFR polymorphism is associated with essential hypertension, coronary artery disease, and higher homocysteine levels. Archives of medical research, 2008, 39, (1), 125-130.
30. Tsai, M. Y.; Welge, B. G.; Hanson, N. Q.; Bignell, M. K.; Vessey, J.; Schwichtenberg, K.; Yang, F.; Bullemer, F. E.; Rasmussen, R.; Graham, K. J., Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases. Atherosclerosis, 1999, 143, (1), 163-170.
31. Urreizti, R.; Asteggiano, C.; Bermudez, M.; Cordoba, A.; Szlago, M.; Grosso, C.; De Kremer, R. D.; Vilarinho, L.; D'Almeida, V.; Martinez-Pardo, M.; Pena-Quintana, L.; Dalmau, J.; Bernal, J.; Briceno, I.; Couce, M. L.; Rodes, M.; Vilaseca, M. A.; Balcells, S.; Grinberg, D., The p. T191M mutation of the CBS gene is highly prevalent among homocystinuric patients from Spain, Portugal and South America. Journal of human genetics, 2006, 51, (4), 305-313.
32. Blom, H. J.; Smulders, Y., Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. Journal of inherited metabolic disease, 2011, 34, (1), 75-81.
33. Kim, Y. I., Folic acid fortification and supplementation-good for some but not so good for others. Nutrition reviews, 2007, 65, (11), 504-511.
34. Robinson, K.; Mayer, E. L.; Miller, D. P.; Green, R.; Van Lente, F.; Gupta, A.; Kottke-Marchant, K.; Savon, S. R.; Selhub, J.; Nissen, S. E.; et al., Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation, 1995, 92, (10), 2825-2830.
35. Friedman, A. N.; Bostom, A. G.; Selhub, J.; Levey, A. S.; Rosenberg, I. H., The kidney and homocysteine metabolism. Journal of the American Society of Nephrology: JASN, 2001, 12, (10), 2181-2189.
36. Guttormsen, A. B.; Ueland, P. M.; Svarstad, E.; Refsum, H., Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney international, 1997, 52, (2), 495-502.
37. Garibotto, G.; Sofia, A.; Valli, A.; Tarroni, A.; Di Martino, M.; Cappelli, V.; Aloisi, F.; Procopio, V., Causes of hyperhomocysteinemia in patients with chronic kidney diseases. Seminars in nephrology, 2006, 26, (1), 3-7.
38. Van Guldener, C.; Kulik, W.; Berger, R.; Dijkstra, D. A.; Jakobs, C.; Reijngoud, D. J.; Donker, A. J.; Stehouwer, C. D.; De Meer, K., Homocysteine and methionine metabolism in ESRD: A stable isotope study. Kidney international, 1999, 56, (3), 1064-1071.
39. Van Guldener, C., Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, 21, (5), 1161-1166.
40. Van Guldener, C.; Janssen, M. J.; Lambert, J.; Ter Wee, P. M.; Donker, A. J.; Stehouwer, C. D., Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Peritoneal dialysis international: journal of the International Society for Peritoneal Dialysis, 1998, 18, (3), 282-289.
41. Wrone, E. M.; Hornberger, J. M.; Zehnder, J. L.; McCann, L. M.; Coplon, N. S.; Fortmann, S. P., Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. Journal of the American Society of Nephrology: JASN, 2004, 15, (2), 420-426.
42. Jamison, R. L.; Hartigan, P.; Kaufman, J. S.; Goldfarb, D. S.; Warren, S. R.; Guarino, P. D.; Gaziano, J. M.; Veterans Affairs Site, I., Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA: the journal of the American Medical Association, 2007, 298, (10), 1163-1170.
43. Wald, D. S.; Law, M.; Morris, J. K., Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Bmj, 2002, 325, (7374), 1202.
44. Wald, D. S.; Wald, N. J.; Morris, J. K.; Law, M., Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. Bmj, 2006, 333, (7578), 1114-1117.
45. Yi, F.; Li, P. L., Mechanisms of homocysteine-induced glomerular injury and sclerosis. American journal of nephrology, 2008, 28, (2), 254-264.
46. Terwecoren, A.; Steen, E.; Benoit, D.; Boon, P.; Hemelsoet, D., Ischemic stroke and hyperhomocysteinemia: truth or myth? Acta neurologica Belgica, 2009, 109, (3), 181-188.
47. Tyagi, S. C.; Smiley, L. M.; Mujumdar, V. S., Homocyst (e) ine impairs endocardial endothelial function. Canadian journal of physiology and pharmacology, 1999, 77, (12), 950-957.
48. Tyagi, S. C.; Smiley, L. M.; Mujumdar, V. S.; Clonts, B.; Parker, J. L., Reduction-oxidation (Redox) and vascular tissue level of homocyst (e) ine in human coronary atherosclerotic lesions and role in extracellular matrix remodeling and vascular tone. Molecular and cellular biochemistry, 1998, 181, (1-2), 107-116.
49. Bedard, K.; Krause, K. H., The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiological reviews, 2007, 87, (1), 245-313.
50. Nauseef, W. M., Biological roles for the NOX family NADPH oxidases. The Journal of biological chemistry, 2008, 283, (25), 16961-16965.
51. Ago, T.; Kitazono, T.; Ooboshi, H.; Iyama, T.; Han, Y. H.; Takada, J.; Wakisaka, M.; Ibayashi, S.; Utsumi, H.; Iida, M., Nox4 as the major catalytic component of an endothelial NAD (P) H oxidase. Circulation, 2004, 109, (2), 227-233.
52. Ago, T.; Kitazono, T.; Kuroda, J.; Kumai, Y.; Kamouchi, M.; Ooboshi, H.; Wakisaka, M.; Kawahara, T.; Rokutan, K.; Ibayashi, S.; Iida, M., NAD (P) H oxidases in rat basilar arterial endothelial cells. Stroke; a journal of cerebral circulation, 2005, 36, (5), 1040-1046.
53. Rhee, S. G., Cell signaling. H2O2, a necessary evil for cell signaling. Science, 2006, 312, (5782), 1882-1883.
54. Au-Yeung, K. K.; Woo, C. W.; Sung, F. L.; Yip, J. C.; Siow, Y. L.; O, K., Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circulation research, 2004, 94, (1), 28-36.
55. Topal, G.; Brunet, A.; Millanvoye, E.; Boucher, J. L.; Rendu, F.; Devynck, M. A.; David-Dufilho, M., Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. Free radical biology & medicine, 2004, 36, (12), 1532-1541.
56. Hoffman, M., Hypothesis: hyperhomocysteinemia is an indicator of oxidant stress. Medical hypotheses, 2011, 77, (6), 1088-1093.
57. Loscalzo, J., The oxidant stress of hyperhomocyst (e) inemia. The Journal of clinical investigation, 1996, 98, (1), 5-7.
58. Sen, U.; Mishra, P. K.; Tyagi, N.; Tyagi, S. C., Homocysteine to hydrogen sulfide or hypertension. Cell biochemistry and biophysics, 2010, 57, (2-3), 49-58.
59. Tyagi, N.; Sedoris, K. C.; Steed, M.; Ovechkin, A. V.; Moshal, K. S.; Tyagi, S. C., Mechanisms of homocysteine-induced oxidative stress. American journal of physiology. Heart and circulatory physiology, 2005, 289, (6), H2649-2656.
60. Weiss, N.; Zhang, Y. Y.; Heydrick, S.; Bierl, C.; Loscalzo, J., Overexpression of cellular glutathione peroxidase rescues homocyst (e) ine-induced endothelial dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, (22), 12503-12508.
61. Sawle, P.; Foresti, R.; Green, C. J.; Motterlini, R., Homocysteine attenuates endothelial haem oxygenase-1 induction by nitric oxide (NO) and hypoxia. FEBS letters, 2001, 508, (3), 403-406.
62. Stuhlinger, M. C.; Tsao, P. S.; Her, J. H.; Kimoto, M.; Balint, R. F.; Cooke, J. P., Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation, 2001, 104, (21), 2569-2575.
63. Sena, L. A.; Chandel, N. S., Physiological roles of mitochondrial reactive oxygen species. Molecular cell, 2012, 48, (2), 158-167.
64. Austin, R. C.; Sood, S. K.; Dorward, A. M.; Singh, G.; Shaughnessy, S. G.; Pamidi, S.; Outinen, P. A.; Weitz, J. I., Homocysteinedependent alterations in mitochondrial gene expression, function and structure. Homocysteine and H2O2 act synergistically to enhance mitochondrial damage. The Journal of biological chemistry, 1998, 273, (46), 30808-30817.
65. Ballinger, S. W.; Patterson, C.; Knight-Lozano, C. A.; Burow, D. L.; Conklin, C. A.; Hu, Z.; Reuf, J.; Horaist, C.; Lebovitz, R.; Hunter, G. C.; McIntyre, K.; Runge, M. S., Mitochondrial integrity and function in atherogenesis. Circulation, 2002, 106, (5), 544-549.
66. Madamanchi, N. R.; Runge, M. S., Mitochondrial dysfunction in atherosclerosis. Circulation research, 2007, 100, (4), 460-473.
67. Chou, Y. F.; Yu, C. C.; Huang, R. F., Changes in mitochondrial DNA deletion, content, and biogenesis in folate-deficient tissues of young rats depend on mitochondrial folate and oxidative DNA injuries. The Journal of nutrition, 2007, 137, (9), 2036-2042.
68. Perez-de-Arce, K.; Foncea, R.; Leighton, F., Reactive oxygen species mediates homocysteine-induced mitochondrial biogenesis in human endothelial cells: modulation by antioxidants. Biochemical and biophysical research communications, 2005, 338, (2), 1103-1109.
69. Lee, H. C.; Wei, Y. H., Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. The international journal of biochemistry & cell biology, 2005, 37, (4), 822-834.
70. Papatheodorou, L.; Weiss, N., Vascular oxidant stress and inflammation in hyperhomocysteinemia. Antioxidants & redox signaling, 2007, 9, (11), 1941-1958.
71. Postea, O.; Krotz, F.; Henger, A.; Keller, C.; Weiss, N., Stereospecific and redox-sensitive increase in monocyte adhesion to endothelial cells by homocysteine. Arteriosclerosis, thrombosis, and vascular biology, 2006, 26, (3), 508-513.
72. Silverman, M. D.; Tumuluri, R. J.; Davis, M.; Lopez, G.; Rosenbaum, J. T.; Lelkes, P. I., Homocysteine upregulates vascular cell adhesion molecule-1 expression in cultured human aortic endothelial cells and enhances monocyte adhesion. Arteriosclerosis, thrombosis, and vascular biology, 2002, 22, (4), 587-592.
73. Wang, G.; Woo, C. W.; Sung, F. L.; Siow, Y. L.; O, K., Increased monocyte adhesion to aortic endothelium in rats with hyperhomocysteinemia: role of chemokine and adhesion molecules. Arteriosclerosis, thrombosis, and vascular biology, 2002, 22, (11), 1777-1783.
74. Babior, B. M., NADPH oxidase: an update. Blood, 1999, 93, (5), 1464-1476.
75. Babior, B. M., The NADPH oxidase of endothelial cells. IUBMB life, 2000, 50, (4-5), 267-269.
76. Robinson, J. M.; Ohira, T.; Badwey, J. A., Regulation of the NADPH-oxidase complex of phagocytic leukocytes. Recent insights from structural biology, molecular genetics, and microscopy. Histochemistry and cell biology, 2004, 122, (4), 293-304.
77. Dai, J.; Li, W.; Chang, L.; Zhang, Z.; Tang, C.; Wang, N.; Zhu, Y.; Wang, X., Role of redox factor-1 in hyperhomocysteinemiaaccelerated atherosclerosis. Free radical biology & medicine, 2006, 41, (10), 1566-1577.
78. Gerdes, V. E.; Hovinga, H. A.; Ten Cate, H.; Macgillavry, M. R.; Leijte, A.; Reitsma, P. H.; Brandjes, D. P.; Buller, H. R.; Amsterdam Vascular Medicine, G., Homocysteine and markers of coagulation and endothelial cell activation. Journal of thrombosis and haemostasis: JTH, 2004, 2, (3), 445-451.
79. Kyrle, P. A.; Stumpflen, A.; Hirschl, M.; Bialonczyk, C.; Herkner, K.; Speiser, W.; Weltermann, A.; Kaider, A.; Pabinger, I.; Lechner, K.; Eichinger, S., Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism. Thrombosis and haemostasis, 1997, 78, (5), 1327-1331.
80. Al-Obaidi, M. K.; Philippou, H.; Stubbs, P. J.; Adami, A.; Amersey, R.; Noble, M. M.; Lane, D. A., Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes. Circulation, 2000, 101, (4), 372-377.
81. Nishinaga, M.; Ozawa, T.; Shimada, K., Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. The Journal of clinical investigation, 1993, 92, (3), 1381-1386.
82. Lentz, S. R.; Sobey, C. G.; Piegors, D. J.; Bhopatkar, M. Y.; Faraci, F. M.; Malinow, M. R.; Heistad, D. D., Vascular dysfunction in monkeys with diet-induced hyperhomocyst (e) inemia. The Journal of clinical investigation, 1996, 98, (1), 24-29.
83. Palareti, G.; Coccheri, S., Lowered antithrombin III activity and other clotting changes in homocystinuria: effects of a pyridoxinefolate regimen. Haemostasis, 1989, 19 Suppl 1, 24-28.
84. Rodgers, G. M.; Conn, M. T., Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood, 1990, 75, (4), 895-901.
85. Hayashi, T.; Honda, G.; Suzuki, K., An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood, 1992, 79, (11), 2930-2936.
86. Harpel, P. C.; Chang, V. T.; Borth, W., Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, (21), 10193-10197.
87. Hajjar, K. A., Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. The Journal of clinical investigation, 1993, 91, (6), 2873-2879.
88. Weiss, N.; Heydrick, S.; Zhang, Y. Y.; Bierl, C.; Cap, A.; Loscalzo, J., Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-deficient mice. Arteriosclerosis, thrombosis, and vascular biology, 2002, 22, (1), 34-41.
89. Zeng, X. K.; Remick, D. G.; Wang, X., Homocysteine induces production of monocyte chemoattractant protein-1 and interleukin-8 in cultured human whole blood. Acta pharmacologica Sinica, 2004, 25, (11), 1419-1425.
90. Zeng, X.; Dai, J.; Remick, D. G.; Wang, X., Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circulation research, 2003, 93, (4), 311-320.
91. Wang, G.; O, K., Homocysteine stimulates the expression of monocyte chemoattractant protein-1 receptor (CCR2) in human monocytes: possible involvement of oxygen free radicals. The Biochemical journal, 2001, 357, (Pt 1), 233-240.
92. Wagner, J. G.; Roth, R. A., Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature. Pharmacological reviews, 2000, 52, (3), 349-374.
93. Guo, X.; Dudman, N. P., Homocysteine induces expressions of adhesive molecules on leukocytes in whole blood. Chinese medical journal, 2001, 114, (12), 1235-1239.
94. Alvarez-Maqueda, M.; El Bekay, R.; Monteseirin, J.; Alba, G.; Chacon, P.; Vega, A.; Santa Maria, C.; Tejedo, J. R.; Martin-Nieto, J.; Bedoya, F. J.; Pintado, E.; Sobrino, F., Homocysteine enhances superoxide anion release and NADPH oxidase assembly by human neutrophils. Effects on MAPK activation and neutrophil migration. Atherosclerosis, 2004, 172, (2), 229-238.
95. Cai, Y.; Zhang, C.; Nawa, T.; Aso, T.; Tanaka, M.; Oshiro, S.; Ichijo, H.; Kitajima, S., Homocysteine-responsive ATF3 gene expression in human vascular endothelial cells: activation of c-Jun. NH (2)-terminal kinase and promoter response element. Blood, 2000, 96, (6), 2140-2148.
96. Von Hundelshausen, P.; Weber, C., Platelets as immune cells: bridging inflammation and cardiovascular disease. Circulation research, 2007, 100, (1), 27-40.
97. Riba, R.; Nicolaou, A.; Troxler, M.; Homer-Vaniasinkam, S.; Naseem, K. M., Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis, 2004, 175, (1), 69-75.
98. Durand, P.; Prost, M.; Blache, D., Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis, 1996, 121, (2), 231-243.
99. Leoncini, G.; Bruzzese, D.; Signorello, M. G., Activation of p38 MAPKinase/cPLA2 pathway in homocysteine-treated platelets. Journal of thrombosis and haemostasis: JTH, 2006, 4, (1), 209-216.
100. Leoncini, G.; Bruzzese, D.; Signorello, M. G., A role for PLCgamma2 in platelet activation by homocysteine. Journal of cellular biochemistry, 2007, 100, (5), 1255-1265.
101. Wang, R., Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter? FASEB journal: official publication of the Federation of American Societies for Experimental Biology, 2002, 16, (13), 1792-1798.
102. Hosoki, R.; Matsuki, N.; Kimura, H., The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. Biochemical and biophysical research communications, 1997, 237, (3), 527-531.
103. Zhao, W.; Zhang, J.; Lu, Y.; Wang, R., The vasorelaxant effect of H (2) S as a novel endogenous gaseous K (ATP) channel opener. The EMBO journal, 2001, 20, (21), 6008-6016.
104. Yang, G.; Wu, L.; Jiang, B.; Yang, W.; Qi, J.; Cao, K.; Meng, Q.; Mustafa, A. K.; Mu, W.; Zhang, S.; Snyder, S. H.; Wang, R., H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science, 2008, 322, (5901), 587-590.
105. Weisiger, R. A.; Pinkus, L. M.; Jakoby, W. B., Thiol Smethyltransferase: suggested role in detoxication of intestinal hydrogen sulfide. Biochemical pharmacology, 1980, 29, (20), 2885-2887.
106. Levitt, M. D.; Furne, J.; Springfield, J.; Suarez, F.; DeMaster, E., Detoxification of hydrogen sulfide and methanethiol in the cecal mucosa. The Journal of clinical investigation, 1999, 104, (8), 1107-1114.
107. Whiteman, M.; Armstrong, J. S.; Chu, S. H.; Jia-Ling, S.; Wong, B. S.; Cheung, N. S.; Halliwell, B.; Moore, P. K., The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite 'scavenger'? Journal of neurochemistry, 2004, 90, (3), 765-768.
108. Chang, L.; Geng, B.; Yu, F.; Zhao, J.; Jiang, H.; Du, J.; Tang, C., Hydrogen sulfide inhibits myocardial injury induced by homocysteine in rats. Amino acids, 2008, 34, (4), 573-585.
109. Kubo, S.; Kajiwara, M.; Kawabata, A., Dual modulation of the tension of isolated gastric artery and gastric mucosal circulation by hydrogen sulfide in rats. Inflammopharmacology, 2007, 15, (6), 288-292.
110. Cheng, Y.; Ndisang, J. F.; Tang, G.; Cao, K.; Wang, R., Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. American journal of physiology. Heart and circulatory physiology, 2004, 287, (5), H2316-2323.
111. Webb, G. D.; Lim, L. H.; Oh, V. M.; Yeo, S. B.; Cheong, Y. P.; Ali, M. Y.; El Oakley, R.; Lee, C. N.; Wong, P. S.; Caleb, M. G.; Salto-Tellez, M.; Bhatia, M.; Chan, E. S.; Taylor, E. A.; Moore, P. K., Contractile and vasorelaxant effects of hydrogen sulfide and its biosynthesis in the human internal mammary artery. The Journal of pharmacology and experimental therapeutics, 2008, 324, (2), 876-882.
112. Ahmad, F. U.; Sattar, M. A.; Rathore, H. A.; Abdullah, M. H.; Tan, S.; Abdullah, N. A.; Johns, E. J., Exogenous hydrogen sulfide (H2S) reduces blood pressure and prevents the progression of diabetic nephropathy in spontaneously hypertensive rats. Renal failure, 2012, 34, (2), 203-210.
113. Chunyu, Z.; Junbao, D.; Dingfang, B.; Hui, Y.; Xiuying, T.; Chaoshu, T., The regulatory effect of hydrogen sulfide on hypoxic pulmonary hypertension in rats. Biochemical and biophysical research communications, 2003, 302, (4), 810-816.
114. Yanfei, W.; Lin, S.; Junbao, D.; Chaoshu, T., Impact of L-arginine on hydrogen sulfide/cystathionine-gamma-lyase pathway in rats with high blood flow-induced pulmonary hypertension. Biochemical and biophysical research communications, 2006, 345, (2), 851-857.
115. Papapetropoulos, A.; Pyriochou, A.; Altaany, Z.; Yang, G.; Marazioti, A.; Zhou, Z.; Jeschke, M. G.; Branski, L. K.; Herndon, D. N.; Wang, R.; Szabo, C., Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, (51), 21972-21977.
116. Chen, L.; Ingrid, S.; Ding, Y. G.; Liu, Y.; Qi, J. G.; Tang, C. S.; Du, J. B., Imbalance of endogenous homocysteine and hydrogen sulfide metabolic pathway in essential hypertensive children. Chinese medical journal, 2007, 120, (5), 389-393.
117. Shi, Y. X.; Chen, Y.; Zhu, Y. Z.; Huang, G. Y.; Moore, P. K.; Huang, S. H.; Yao, T.; Zhu, Y. C., Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats. American journal of physiology. Heart and circulatory physiology, 2007, 293, (4), H2093-2100.
118. Zhao, X.; Zhang, L. K.; Zhang, C. Y.; Zeng, X. J.; Yan, H.; Jin, H. F.; Tang, C. S.; Du, J. B., Regulatory effect of hydrogen sulfide on vascular collagen content in spontaneously hypertensive rats. Hypertension research: official journal of the Japanese Society of Hypertension, 2008, 31, (8), 1619-1630.
119. Wang, Y.; Zhao, X.; Jin, H.; Wei, H.; Li, W.; Bu, D.; Tang, X.; Ren, Y.; Tang, C.; Du, J., Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Arteriosclerosis, thrombosis, and vascular biology, 2009, 29, (2), 173-179.
120. Zagli, G.; Patacchini, R.; Trevisani, M.; Abbate, R.; Cinotti, S.; Gensini, G. F.; Masotti, G.; Geppetti, P., Hydrogen sulfide inhibits human platelet aggregation. European journal of pharmacology, 2007, 559, (1), 65-68.
121. Li, L.; Bhatia, M.; Zhu, Y. Z.; Zhu, Y. C.; Ramnath, R. D.; Wang, Z. J.; Anuar, F. B.; Whiteman, M.; Salto-Tellez, M.; Moore, P. K., Hydrogen sulfide is a novel mediator of lipopolysaccharideinduced inflammation in the mouse. FASEB journal: official publication of the Federation of American Societies for Experimental Biology, 2005, 19, (9), 1196-1198.
122. Bhatia, M.; Wong, F. L.; Fu, D.; Lau, H. Y.; Moochhala, S. M.; Moore, P. K., Role of hydrogen sulfide in acute pancreatitis and associated lung injury. FASEB journal: official publication of the Federation of American Societies for Experimental Biology, 2005, 19, (6), 623-625.
123. Li, L.; Rossoni, G.; Sparatore, A.; Lee, L. C.; Del Soldato, P.; Moore, P. K., Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free radical biology & medicine, 2007, 42, (5), 706-719.
124. Whiteman, M.; Li, L.; Rose, P.; Tan, C. H.; Parkinson, D. B.; Moore, P. K., The effect of hydrogen sulfide donors on lipopolysaccharideinduced formation of inflammatory mediators in macrophages. Antioxidants & redox signaling, 2010, 12, (10), 1147-1154.
125. Fiorucci, S.; Orlandi, S.; Mencarelli, A.; Caliendo, G.; Santagada, V.; Distrutti, E.; Santucci, L.; Cirino, G.; Wallace, J. L., Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. British journal of pharmacology, 2007, 150, (8), 996-1002.
126. Zanardo, R. C.; Brancaleone, V.; Distrutti, E.; Fiorucci, S.; Cirino, G.; Wallace, J. L., Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB journal: official publication of the Federation of American Societies for Experimental Biology, 2006, 20, (12), 2118-2120.
127. Tripatara, P.; Patel, N. S.; Collino, M.; Gallicchio, M.; Kieswich, J.; Castiglia, S.; Benetti, E.; Stewart, K. N.; Brown, P. A.; Yaqoob, M. M.; Fantozzi, R.; Thiemermann, C., Generation of endogenous hydrogen sulfide by cystathionine gamma-lyase limits renal ischemia/reperfusion injury and dysfunction. Laboratory investigation; a journal of technical methods and pathology, 2008, 88, (10), 1038-1048.
128. Sivarajah, A.; McDonald, M. C.; Thiemermann, C., The production of hydrogen sulfide limits myocardial ischemia and reperfusion injury and contributes to the cardioprotective effects of preconditioning with endotoxin, but not ischemia in the rat. Shock, 2006, 26, (2), 154-161.
129. Kimura, Y.; Dargusch, R.; Schubert, D.; Kimura, H., Hydrogen sulfide protects HT22 neuronal cells from oxidative stress. Antioxidants & redox signaling, 2006, 8, (3-4), 661-670.
130. Kimura, Y.; Goto, Y.; Kimura, H., Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxidants & redox signaling, 2010, 12, (1), 1-13.
131. Sen, U.; Basu, P.; Abe, O. A.; Givvimani, S.; Tyagi, N.; Metreveli, N.; Shah, K. S.; Passmore, J. C.; Tyagi, S. C., Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. American journal of physiology. Renal physiology, 2009, 297, (2), F410-419.
132. Yan, S. K.; Chang, T.; Wang, H.; Wu, L.; Wang, R.; Meng, Q. H., Effects of hydrogen sulfide on homocysteine-induced oxidative stress in vascular smooth muscle cells. Biochemical and biophysical research communications, 2006, 351, (2), 485-491.
133. Whiteman, M.; Li, L.; Kostetski, I.; Chu, S. H.; Siau, J. L.; Bhatia, M.; Moore, P. K., Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide. Biochemical and biophysical research communications, 2006, 343, (1), 303-310.
134. Kubo, S.; Kurokawa, Y.; Doe, I.; Masuko, T.; Sekiguchi, F.; Kawabata, A., Hydrogen sulfide inhibits activity of three isoforms of recombinant nitric oxide synthase. Toxicology, 2007, 241, (1-2), 92-97.
135. Geng, B.; Cui, Y.; Zhao, J.; Yu, F.; Zhu, Y.; Xu, G.; Zhang, Z.; Tang, C.; Du, J., Hydrogen sulfide downregulates the aortic Larginine/nitric oxide pathway in rats. American journal of physiology. Regulatory, integrative and comparative physiology, 2007, 293, (4), R1608-1618.
136. Kubo, S.; Doe, I.; Kurokawa, Y.; Nishikawa, H.; Kawabata, A., Direct inhibition of endothelial nitric oxide synthase by hydrogen sulfide: contribution to dual modulation of vascular tension. Toxicology, 2007, 232, (1-2), 138-146.
137. Oh, G. S.; Pae, H. O.; Lee, B. S.; Kim, B. N.; Kim, J. M.; Kim, H. R.; Jeon, S. B.; Jeon, W. K.; Chae, H. J.; Chung, H. T., Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. Free radical biology & medicine, 2006, 41, (1), 106-119.
138. Bir, S. C.; Kolluru, G. K.; McCarthy, P.; Shen, X.; Pardue, S.; Pattillo, C. B.; Kevil, C. G., Hydrogen sulfide stimulates ischemic vascular remodeling through nitric oxide synthase and nitrite reduction activity regulating hypoxia-inducible factor-1alpha and vascular endothelial growth factor-dependent angiogenesis. Journal of the American Heart Association, 2012, 1, (5), e004093.
139. Altaany, Z.; Yang, G.; Wang, R., Crosstalk between hydrogen sulfide and nitric oxide in endothelial cells. Journal of cellular and molecular medicine, 2013, 17, (7), 879-888.
140. Eto, K.; Kimura, H., A novel enhancing mechanism for hydrogen sulfide-producing activity of cystathionine beta-synthase. The Journal of biological chemistry, 2002, 277, (45), 42680-42685.
141. Zhao, W.; Ndisang, J. F.; Wang, R., Modulation of endogenous production of H2S in rat tissues. Canadian journal of physiology and pharmacology, 2003, 81, (9), 848-853.
142. Anuar, F.; Whiteman, M.; Siau, J. L.; Kwong, S. E.; Bhatia, M.; Moore, P. K., Nitric oxide-releasing flurbiprofen reduces formation of proinflammatory hydrogen sulfide in lipopolysaccharide-treated rat. British journal of pharmacology, 2006, 147, (8), 966-974.